论文部分内容阅读
目的:探讨蛋白芯片联合检测多种肿瘤标志物在恶性肿瘤的诊断和筛查中的价值。方法:采用多种肿瘤标志物蛋白芯片系统测定分析308例恶性肿瘤患者,172例良性疾病患者和926例健康体检者血清中的12种肿瘤标志物(CA199、CEA、AFP、CA242、CA125、CA153、NSE、β-HCG、f-PSA、PSA、HCH、FER)的含量。结果:恶性肿瘤组的阳性率(73.05%)显著高于良性疾病组(31.98%)和健康体检组(11.56%)(P<0.001);除胰腺癌外,多种肿瘤标志物联合检测对肺癌、胃癌、结直肠癌、食管癌、肝癌和乳腺癌检出阳性率均显著高于其单一肿瘤标志物检测(P<0.01)。结论:蛋白芯片联合检测血清多种肿瘤标志物可以显著提高恶性肿瘤诊断的敏感性,对肿瘤的早期诊断具有一定的应用价值,尤其适用于体检筛查。
Objective: To investigate the value of protein chip in the detection and screening of many tumor markers in malignant tumors. Methods: A total of 12 tumor markers (CA199, CEA, AFP, CA242, CA125, CA153) in serum of 308 patients with malignant tumors, 172 patients with benign diseases and 926 healthy subjects were analyzed by a variety of tumor marker protein chip system. , NSE, β-HCG, f-PSA, PSA, HCH, FER). Results: The positive rate of malignant tumor group (73.05%) was significantly higher than that of benign disease group (31.98%) and healthy group (11.56%) (P <0.001). In addition to pancreatic cancer, a variety of tumor markers combined detection of lung cancer The positive rates of gastric cancer, colorectal cancer, esophageal cancer, liver cancer and breast cancer were significantly higher than those of single tumor markers (P <0.01). Conclusion: The combination of protein microarray and serum detection of multiple tumor markers can significantly improve the sensitivity of malignant tumor diagnosis, and has certain value in the early diagnosis of tumors, especially suitable for physical screening.